Thetis Pharmaceuticals Receives $1 Million NIH Commercialization Readiness Pilot Award to Advance Oral TP-317 for Ulcerative Colitis
ESSEX, Conn. — September 17, 2026 — Thetis Pharmaceuticals, LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD), today announced that it has received a $1 million Small Business Innovation Research (SBIR) Commercialization Readiness Pilot award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The award funds GLP nonclinical toxicology studies required to advance TP-317 beyond the Phase 1b trial in patients with moderate-to-severe ulcerative colitis.
“Continued support from NIDDK enables us to complete the nonclinical program for later-stage development in parallel with our Phase 1b trial,” said Gary Mathias, co-founder and CEO of Thetis.
Research reported in this press release is supported by NIDDK under Award Number SB1DK145287. The content is solely the responsibility of Thetis Pharmaceuticals and does not necessarily represent the official views of the NIH.
About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing new therapies for IBD and oncology. Thetis' lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug candidate that engages the BLT1 receptor to activate the body’s natural ability to restore tissue and immune homeostasis. In a Phase 1a study, TP-317 was well tolerated and demonstrated target engagement. A Phase 1b proof-of-mechanism trial in moderate-to-severe ulcerative colitis patients will begin recruiting in Q4-2026. Thetis is supported by the Helmsley Charitable Trust, the Crohn's & Colitis Foundation, the Kenneth Rainin Foundation, the National Institutes of Health (NIH), and private investors.
Contact Information
Tracy Lessor
TLOW Communications
617-519-9827
tracy@tlowcommunications.com